Prometrium Compounding Legal Status: FDA Approval, Label Details, and What Patients Need to Know

FDA Approval History of Prometrium

The FDA approved Prometrium (NDA 019781) in 1998 under Solvay Pharmaceuticals for two indications: treatment of secondary amenorrhea and prevention of endometrial hyperplasia in postmenopausal women taking conjugated estrogens [1]. This approval followed years of clinical evidence, most notably the PEPI trial.

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, published in JAMA in 1995 (N=875), compared oral micronized progesterone to medroxyprogesterone acetate (MPA) in combination with conjugated equine estrogens. PEPI demonstrated that micronized progesterone preserved the beneficial effects of estrogen on HDL cholesterol while still protecting the endometrium [2]. Specifically, women receiving 200 mg of micronized progesterone cyclically experienced a 4.1 mg/dL increase in HDL-C, compared to a nonsignificant decrease in HDL-C with MPA [2].

Solvay Pharmaceuticals was later acquired by Abbott Laboratories in 2010, and the Prometrium brand subsequently transferred to AbbVie when Abbott spun off its research-based pharmaceutical division in 2013. AbbVie remains the current holder of the Prometrium NDA. Generic versions of micronized progesterone 100 mg and 200 mg capsules have been available since the early 2010s, giving prescribers and patients multiple commercially manufactured options [1].

The FDA's Drugs@FDA database confirms that Prometrium retains active approval status, and the label has been updated multiple times to reflect post-market safety data, including a boxed warning added after the Women's Health Initiative (WHI) findings in 2002 [3].

What the Prometrium Label Says

The current Prometrium prescribing information specifies two approved uses: oral administration of 200 mg daily for 12 days sequentially per 28-day cycle for endometrial protection, and 400 mg daily for 10 days for secondary amenorrhea [1]. The label is narrow. It does not cover compounded formulations, vaginal administration, or luteal phase support in fertility treatment.

A boxed warning states: "Estrogens plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia" [1]. This language derives from WHI findings where combined hormone therapy with MPA (not micronized progesterone) increased breast cancer incidence by 26% over 5.6 years (HR 1.26, 95% CI 1.00-1.59) [3]. The FDA applied the class-wide warning to all progestins, including Prometrium, despite the absence of identical trial data for micronized progesterone.

One clinically relevant label detail: Prometrium capsules contain peanut oil. The label carries a contraindication for patients with known peanut allergy [1]. This specific excipient is one reason prescribers sometimes turn to compounded alternatives. Generic micronized progesterone capsules from some manufacturers also use peanut oil, though not all do. Prescribers should verify inactive ingredients on a per-manufacturer basis.

The label also notes that micronized progesterone is derived from plant sources (wild yam, Dioscorea) and then pharmaceutically synthesized. This is the same starting material used by compounding pharmacies producing "bioidentical" progesterone, a term the FDA does not recognize as a regulatory category [4].

The Legal Framework for Compounding Progesterone

Compounding of micronized progesterone is legal but regulated. Two sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act) govern this area, and the distinction matters for patients and prescribers.

Section 503A applies to traditional compounding pharmacies. Under 503A, a licensed pharmacist may compound a drug for an individual patient based on a valid prescription from a licensed prescriber [5]. The compounded product must not be a copy of a commercially available drug unless the prescriber documents a clinical difference (such as an allergy to an inactive ingredient in the FDA-approved version or a need for a dosage form not commercially available). Because Prometrium capsules are commercially available in 100 mg and 200 mg strengths, a 503A pharmacy compounding the same oral capsule at the same strength could face regulatory scrutiny unless a patient-specific clinical need is documented [5].

Section 503B applies to outsourcing facilities, which are registered with the FDA and subject to current Good Manufacturing Practice (cGMP) requirements. These facilities may compound without individual patient prescriptions and distribute to healthcare facilities. Outsourcing facilities producing micronized progesterone must comply with cGMP standards, report adverse events, and label products with specific information including a statement that the product is compounded [5].

The FDA has stated its position clearly. In a 2020 statement, then-FDA Commissioner Dr. Stephen Hahn noted: "Compounded drugs are not FDA-approved. This means they have not undergone FDA evaluation for safety, effectiveness, or quality before marketing" [6]. This applies equally to compounded progesterone, regardless of whether the active ingredient is chemically identical to Prometrium.

Micronized progesterone powder (the bulk drug substance) is available on the FDA's list of bulk drug substances that can be used in compounding under section 503A. It is not on the "difficult to compound" list or the withdrawn/removed list, which means compounding pharmacies can legally source and use it [5]. The National Academies of Sciences, Engineering, and Medicine (NASEM) published a 2020 report examining the clinical utility of compounded bioidentical hormone therapy and concluded that "there is insufficient evidence to support claims that [compounded bioidentical hormones] are safer or more effective than FDA-approved hormone therapies" [7].

Compounded vs. FDA-Approved: Clinical and Quality Differences

The active molecule in compounded micronized progesterone and Prometrium is the same. The differences are in manufacturing oversight, quality assurance, and dosage form availability. Those differences are not trivial.

FDA-approved Prometrium undergoes batch-by-batch quality testing, bioequivalence studies, and stability testing under controlled conditions. A 2001 study published in Obstetrics & Gynecology analyzed compounded hormone preparations from 37 pharmacies and found that 34% of compounded progesterone products failed potency testing, delivering less than 90% or more than 110% of the labeled dose [8]. The FDA-approved product must meet USP specifications of 90-110% label claim for every batch released.

Compounding pharmacies offer dosage forms that Prometrium does not. These include vaginal suppositories, sublingual troches, topical creams, and rectal formulations. The vaginal route in particular has clinical utility: the American Society for Reproductive Medicine (ASRM) practice committee has stated that "vaginal progesterone is an acceptable alternative to intramuscular progesterone for luteal phase support in IVF" [9]. No FDA-approved oral micronized progesterone product carries this indication. A separate FDA-approved vaginal progesterone product (Endometrin, 100 mg vaginal insert, and Crinone, 8% vaginal gel) exists for luteal support, but these are different formulations with different pharmacokinetics.

For patients with a documented peanut allergy, compounded micronized progesterone capsules without peanut oil represent a legitimate clinical need that satisfies the 503A "clinical difference" requirement. The Endocrine Society's 2019 scientific statement on bioidentical hormones recommended that "when an FDA-approved product is available, it should be used in preference to a compounded product" but acknowledged allergy-related exceptions [10].

State-Level Regulation and Variability

Federal law sets the floor. State pharmacy boards set additional requirements that directly affect patient access to compounded progesterone.

Some states require compounding pharmacies to hold specific licenses beyond a standard pharmacy permit. California, for example, requires a separate "sterile compounding" license for any pharmacy preparing injectable or implantable compounded products. Texas requires compounding pharmacies to register with the Texas State Board of Pharmacy and comply with additional inspection schedules. These requirements do not prohibit compounding of micronized progesterone but add compliance layers that affect which pharmacies offer it [5].

Certain states have also enacted legislation addressing "bioidentical hormone" marketing claims. The North American Menopause Society (NAMS) 2022 position statement noted: "The term 'bioidentical' has been used in ways that are misleading, implying that these hormones are natural and therefore safer. FDA-approved micronized progesterone is itself bioidentical to endogenous progesterone" [11]. This distinction is important: Prometrium and compounded micronized progesterone share the identical molecular structure (C₂₁H₃₀O₂). The "bioidentical" label does not confer a safety advantage on the compounded version.

Prescribers should verify their state pharmacy board's current compounding regulations before directing patients to a compounding pharmacy, as enforcement activity has increased. The FDA issued 70+ warning letters to compounding pharmacies between 2018 and 2023, several of which involved hormone preparations [6].

Safety Considerations Specific to Compounded Progesterone

Post-market safety monitoring for compounded drugs is limited compared to FDA-approved products. The FDA's MedWatch system captures adverse events for approved drugs through mandatory manufacturer reporting. Compounding pharmacies under 503A have no mandatory adverse event reporting obligation. Only 503B outsourcing facilities must report adverse events to the FDA [5].

This gap creates a surveillance blind spot. The WHI and its extensions generated over two decades of follow-up data on progestin safety in postmenopausal women [3]. No comparable long-term dataset exists for compounded progesterone formulations. A 2019 analysis in the FDA Sentinel System database, which covers over 100 million patient records, found that approximately 26-34 million prescriptions for progesterone were dispensed annually in the United States, but the system cannot distinguish compounded from manufactured fills [12].

The Endocrine Society's 2019 statement identified specific safety concerns with compounded hormones: inconsistent potency, contamination risk, lack of patient medication guides, and absence of FDA-required boxed warnings on product labeling [10]. A compounded progesterone cream or troche will not carry the WHI-derived cardiovascular and breast cancer warnings that appear on every Prometrium package.

For patients who have a legitimate clinical reason to use compounded progesterone (allergy, need for a non-oral route not available in an FDA-approved product), the safest approach is to use a 503B outsourcing facility that operates under cGMP and reports adverse events. Prescribers should document the specific clinical rationale and monitor patients with the same vigilance applied to FDA-approved hormone therapy.

The Role of Professional Society Guidance

Multiple professional societies have weighed in on the compounding question, and their positions are consistent. The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 532, reaffirmed in 2021, states: "There is no evidence that compounded bioidentical hormones are safe or effective... FDA-approved hormone therapy should be the preferred treatment option" [13].

NAMS echoed this in its 2022 hormone therapy position statement, recommending FDA-approved formulations as first-line and reserving compounded hormones for "patients who cannot tolerate an FDA-approved product" [11]. The Endocrine Society and AACE have published similar positions [10].

These recommendations do not make compounding illegal. They establish a clinical hierarchy: use FDA-approved products first, compound only when a documented clinical need exists. This aligns with the FDA's enforcement posture, which targets pharmacies that market compounded hormones as superior to or interchangeable with approved products, not pharmacies filling legitimate patient-specific prescriptions.

The practical effect for patients: if your prescriber recommends micronized progesterone for endometrial protection or amenorrhea, the first-line option is Prometrium or its AB-rated generic. If you have a peanut allergy, need a vaginal formulation not covered by Endometrin or Crinone, or require a non-standard dose, a compounded preparation from a reputable pharmacy (ideally 503B-registered) is the appropriate alternative. Your prescriber should document the reason in your chart.